Do immune checkpoint inhibitors improve survival for first-line Small Cell Lung Cancer treatment?
For people with extensive-stage small-cell lung cancer (ES-SCLC), adding an immune checkpoint inhibitor (ICI) to standard chemotherapy has become a key first-line treatment. Multiple large trials and a meta-analysis show that this combination improves overall survival compared to chemotherapy alone. The benefit is seen specifically in first-line therapy, not in later lines of treatment.
What the research says
A 2025 systematic review and meta-analysis of randomized controlled trials found that ICIs decreased the risk of death by 19% (HR: 0.81, 95% CI: 0.76-0.86) and the risk of disease progression by 22% (HR: 0.78, 95% CI: 0.67-0.91) when used as first-line treatment for ES-SCLC 2. The survival benefit was consistent regardless of age, sex, or performance status 2.
Key phase 3 trials support these findings. The IMpower133 trial showed that adding atezolizumab (a PD-L1 inhibitor) to carboplatin and etoposide improved median overall survival to 12.3 months versus 10.3 months with placebo 8. The ASTRUM-005 trial demonstrated that serplulimab (a PD-1 inhibitor) plus chemotherapy significantly improved overall survival compared to chemotherapy alone 9.
However, the benefit is limited to first-line use. The meta-analysis found no survival benefit and even a detrimental effect on progression-free survival when ICIs were used as second-line therapy 2. This highlights that ICIs are most effective when given early in the treatment course.
Ongoing research is exploring maintenance strategies. Two phase II studies tested tislelizumab plus anti-angiogenic drugs (sitravatinib or anlotinib) as maintenance after first-line chemo-immunotherapy, showing median overall survival of 17.6 months and not yet reached, respectively 6. These results are promising but require confirmation in larger trials.
What to ask your doctor
- Would adding an immune checkpoint inhibitor to my first-line chemotherapy be appropriate for my stage of small-cell lung cancer?
- What are the potential side effects of combining an ICI with chemotherapy, and how are they managed?
- Are there any specific biomarkers, like PD-L1 expression, that help predict benefit from ICI therapy in SCLC?
- What maintenance treatment options are available after completing initial chemo-immunotherapy?
- How does the timing of ICI administration (morning vs. afternoon) affect outcomes, based on recent research?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.